Navigation Links
Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff
Date:5/2/2011

roducts company, and the fourth-largest producer in the world.  The company has implemented an ambitious investment plan to enable it to deliver sustained growth over the next 8 to 10 years.  For more information please visit:  www.grifols.com

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: http://www.talecris.com/

About Kedrion

Kedrion is active in the development, production and distribution of plasma-derived pharmaceutical products used in treating patients affected by haemophilia, immune deficiency, coagulation disorders and other forms of serious diseases. Kedrion, founded in 2001 as business combination of family owned companies, is the Italian leader in the sector and sells in 40 countries around the world. Headquartered in Italy (Castelvecchio Pascoli, near Lucca), Kedrion has two production plants in Italy, in Bolognana and in S. Antimo, and one in Hungary, in Godollo. Kedrion has also 12 plasma collection centers, in the US, Germany and Hungary.

Disclaimer

This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "will," "should" and similar expressions, as they relate to us, are intended to identify forward-looking statements. These statements reflect management's current beliefs, assumptions and expectations and are subject to a number of factors that may cause actual results to differ materially.  These factors include but are
'/>"/>

SOURCE Grifols, S.A.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Grifols Establishes Expert Advisory Council in Transfusion Medicine
2. Grifols Signs Cooperative Agreement for Commercialization of Immunohematology Diagnostic Products in the US
3. Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles)
4. NASDAQ Removes TLCR From Biotechnology Index Pending FTC Decision on Grifols Acquisition
5. Health Robotics CytoCare Continues European Expansion With Grifols and Vall dHebron University Hospital
6. Grifols Agrees to Acquire Intellectual Property for Treatment of Post-Polio Syndrome From Pharmalink AB
7. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
8. Health Robotics CytoCare(TM) Global Expansion Continues With Grifols International in Latin America
9. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
10. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
11. Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015 A power morcellator ... has been settled for an undisclosed amount, Bernstein Liebhard ... filed in March 2014 in the U.S. District Court, ... behalf of a widower whose wife had died in ... a hysterectomy that involved the use of a power ...
(Date:7/7/2015)... According to a new market research ... (Consumables, Instrument), Application (Aerobic, Anaerobic, Yeast/ Fungi) & End User ... to 2019", published by MarketsandMarkets, The global Blood Culture Tests ... $2,750.2 Million in 2014 at a CAGR of 7.2% from ... ma rket data T ables and ...
(Date:7/7/2015)... 7, 2015 C,est ... annonce l,acquisition de 20% du Groupe TRB, ... spécialisée dans la fabrication de médicaments et ...      (Logo: http://photos.prnewswire.com/prnh/20150707/232398LOGO) , ... groupes chimiques et pharmaceutiques italiens, qui contrôle, ...
Breaking Medicine Technology:Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 2Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 2Blood Culture Tests Market Worth $3,893.5 Million by 2019 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 4
... BOULDER, Colo. and MONTREAL, Jan. 9 ... Inc. (TSX: MYG) today announced,the enrollment of ... clinical trial (Trial,CL002) evaluating MGCD0103, the Companies, ... combination with,Vidaza(R) (azacitidine for injection), Pharmion,s DNA ...
... Whatever illness it is, it can make you feel ... but it is even more difficult to handle,being sick ... Diabetes Association (ADA), people with,diabetes who develop an illness ... care of their diabetes. Blood glucose levels can increase,or ...
Cached Medicine Technology:Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 2Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 3Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 4Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 5Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 6Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 7Help! I'm Sick. How Do I Handle My Diabetes? 2
(Date:7/7/2015)... ... 07, 2015 , ... Illinois cannabis cultivation centers and dispensary ... holders. The Medical Cannabis Alliance of Illinois’ (MCAI) board and its members have ... to making sure patients have access to cannabis as a viable medical treatment ...
(Date:7/7/2015)... ... 07, 2015 , ... Summer is a great time to get outside and ... sharing some safety tips. , Jean Tapley, senior wellness coordinator at Amica, suggests the ... , Start slowly. Going from no activity to several hours of activity ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... Detroit was the site of the National Baptist Convention 110th Annual Session of ... encouraging and promoting the collaboration of churches and their congregations, medical professionals and ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... creative design firm, today announced that TimberNook ( http://www.timbernook.com/ ) has ... campaign, content strategy, and marketing launch package for new camp providers. TimberNook ...
(Date:7/7/2015)... AURORA, Colo. (PRWEB) , ... ... ... healthcare landscape relies on highly educated and motivated leaders with strong managerial ... how well they clearly communicate with patients, staff, providers, business partners, insurance ...
Breaking Medicine News(10 mins):Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 3Health News:TimberNook Selects Calypso Communications for PR, Social Media and Content Strategy 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 3Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 4
... Julia VanTine HealthDay Reporter , WEDNESDAY, Oct. 27 ... than commonly thought, say researchers who found a lag time ... mutations and the formation of the first cancer cells. ... this often-fatal disease in its early stages, scientists say. ...
... WEDNESDAY, Oct. 27 (HealthDay News) -- Although many Americans are ... many are controlling the condition, the prevalence of high blood ... health officials report. According to a new ... 30 percent of American adults suffer from hypertension. "Overall, ...
... immune system may play a critical role in ensuring the ... new study by researchers at the Stanford University School of ... oncogenes are much more successful in eradicating tumors in the ... cell called a T helper cell. The finding is ...
... Hatfield Professor of Urology in the Department of Urology at ... honored as the 2010 recipient of the Karl Storz Lifetime ... He is also a full Professor of Radiology. ... the Karl Storz lifetime achievement award; having such a distinguished ...
... , WEDNESDAY, Oct. 27 (HealthDay News) -- With ... expert offers breast cancer survivors some guidance on what ... Karen Syrjala, director of biobehavioral sciences and co-director ... Research Center in Seattle, touches upon both the lingering ...
... A team investigating how genes respond to hormonal changes ... of 1.24 million for a five-year study. The ... Manchester Biomedical Research Centre (BRC) is led by Professor ... and leader of The University of Manchester,s Developmental Biomedicine ...
Cached Medicine News:Health News:Pancreatic Cancer Surprisingly Slow to Arise: Study 2Health News:Pancreatic Cancer Surprisingly Slow to Arise: Study 3Health News:Percentage of U.S. Adults With Hypertension Holds Steady at 30% 2Health News:Certain cancer therapies' success depends on presence of immune cell, Stanford study shows in mice 2Health News:Certain cancer therapies' success depends on presence of immune cell, Stanford study shows in mice 3Health News:Certain cancer therapies' success depends on presence of immune cell, Stanford study shows in mice 4Health News:Jefferson urologist awarded Lifetime Achievement Award from Endourological Society 2Health News:Women Urged to Reclaim Their Life After Breast Cancer 2Health News:Manchester team wins $1.9 million grant for 'cell control' study 2
Up-tapered output compresses NA to give low NA fiber performance on high NA fiber stock....
... AAA Endovascular Graft with the H&L-B One-Shot ... for the endovascular treatment of patients with ... suitable for endovascular repair. The Zenith AAA ... an aneurysm to "seal off" the aneurysm. ...
The new series of Steris Power-lift Stirrups incorporate all of the proven clinical benefits of Allen-style booted stirrups: maximum safety for the patient, ease of setup for your staff, impressive v...
... Pneumatic lift assist stirrups are designed to travel ... -30 degrees. They lock tight wherever you release ... and adduction are done at the handle with ... side rail socket. The rotation of system was ...
Medicine Products: